130 related articles for article (PubMed ID: 29970523)
41. [Reversal of multidrug resistance of tumor cells by FG020327 and its mechanism].
Chen LM; Li YF; Zhang X; Yan SL; Liang YJ; Fu LW
Ai Zheng; 2005 Feb; 24(2):189-93. PubMed ID: 15694031
[TBL] [Abstract][Full Text] [Related]
42. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
43. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Ji BS; He L; Liu GQ
Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
[TBL] [Abstract][Full Text] [Related]
44. Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.
Stark M; Assaraf YG
Oncotarget; 2017 Jul; 8(30):49973-49987. PubMed ID: 28637003
[TBL] [Abstract][Full Text] [Related]
45. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
[TBL] [Abstract][Full Text] [Related]
46. An insight into the structure of 5-spiro aromatic derivatives of imidazolidine-2,4-dione, a new group of very potent inhibitors of tumor multidrug resistance in T-lymphoma cells.
Żesławska E; Kucwaj-Brysz K; Kincses A; Spengler G; Szymańska E; Czopek A; Marć MA; Kaczor A; Nitek W; Domínguez-Álvarez E; Latacz G; Kieć-Kononowicz K; Handzlik J
Bioorg Chem; 2021 Apr; 109():104735. PubMed ID: 33640632
[TBL] [Abstract][Full Text] [Related]
47. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
48. Preliminary studies on phenothiazine-mediated reversal of multidrug resistance in mouse lymphoma and COLO 320 cells.
Pajak B; Molnar J; Engi H; Orzechowski A
In Vivo; 2005; 19(6):1101-4. PubMed ID: 16277030
[TBL] [Abstract][Full Text] [Related]
49. Fluorimetric Methods for Analysis of Permeability, Drug Transport Kinetics, and Inhibition of the ABCB1 Membrane Transporter.
Armada A; Martins C; Spengler G; Molnar J; Amaral L; Rodrigues AS; Viveiros M
Methods Mol Biol; 2016; 1395():87-103. PubMed ID: 26910071
[TBL] [Abstract][Full Text] [Related]
50. N-alkanol-N-cyclohexanol amine aryl esters: Multidrug resistance (MDR) reversing agents with high potency and efficacy.
Teodori E; Dei S; Coronnello M; Floriddia E; Bartolucci G; Manetti D; Romanelli MN; Santo Domingo Porqueras D; Salerno M
Eur J Med Chem; 2017 Feb; 127():586-598. PubMed ID: 28113128
[TBL] [Abstract][Full Text] [Related]
51. Euphorbia factor L1 reverses ABCB1-mediated multidrug resistance involving interaction with ABCB1 independent of ABCB1 downregualtion.
Zhang JY; Mi YJ; Chen SP; Wang F; Liang YJ; Zheng LS; Shi CJ; Tao LY; Chen LM; Chen HB; Fu LW
J Cell Biochem; 2011 Apr; 112(4):1076-83. PubMed ID: 21308736
[TBL] [Abstract][Full Text] [Related]
52. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
[TBL] [Abstract][Full Text] [Related]
53. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X
Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007
[TBL] [Abstract][Full Text] [Related]
54. Effect of cycloartanes on reversal of multidrug resistance and apoptosis induction on mouse lymphoma cells.
Madureira AM; Spengler G; Molnár A; Varga A; Molnár J; Abreu PM; Ferreira MJ
Anticancer Res; 2004; 24(2B):859-64. PubMed ID: 15161038
[TBL] [Abstract][Full Text] [Related]
55. Differential effect of phenothiazines on MRP1 and P-glycoprotein activity.
Wesołowska O; Molnar J; Ocsovszki I; Michalak K
In Vivo; 2009; 23(6):943-7. PubMed ID: 20023237
[TBL] [Abstract][Full Text] [Related]
56. Pharmacological Potential and Synthetic Approaches of Imidazo[4,5-b]pyridine and Imidazo[4,5-c]pyridine Derivatives.
Krause M; Foks H; Gobis K
Molecules; 2017 Mar; 22(3):. PubMed ID: 28273868
[TBL] [Abstract][Full Text] [Related]
57. [Reversal of multidrug resistance in leukemic cell line K562/AO2 by chlordelazine in vitro].
Chen LJ; Shen SH; Wang HM; Ye X; Jiang SY; Gao F; Li GM
Zhonghua Er Ke Za Zhi; 2003 Jul; 41(7):525-7. PubMed ID: 14746680
[TBL] [Abstract][Full Text] [Related]
58. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and structure--activity relationship (SAR) studies of imidazo[4,5-b]pyridine derived purine isosteres and their potential as cytotoxic agents.
Sajith AM; Abdul Khader KK; Joshi N; Reddy MN; Syed Ali Padusha M; Nagaswarupa HP; Nibin Joy M; Bodke YD; Karuvalam RP; Banerjee R; Muralidharan A; Rajendra P
Eur J Med Chem; 2015 Jan; 89():21-31. PubMed ID: 25462222
[TBL] [Abstract][Full Text] [Related]
60. HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
Köhler SC; Wiese M
J Med Chem; 2015 May; 58(9):3910-21. PubMed ID: 25855895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
